0.30Open0.30Pre Close0 Volume27 Open Interest20.00Strike Price0.00Turnover186.17%IV100.20%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type0.1405Delta0.0433Gamma33.80Leverage Ratio-0.0211Theta0.0008Rho4.75Eff Leverage0.0062Vega
Arcutis Biotherapeutics Stock Discussion
Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)
Long-term! 😜
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types | ARQT Stock News
No comment yet